^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RX-af01

    i
    Other names: RX-af01
    Associations

    News

    Trials
    Company:
    Sun Yat-sen University
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    11ms
    Safety and Efficacy of RX-af01 Combined With PD-1 Antibody (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Sun Yat-sen University | N=14 --> 60 | Trial completion date: Sep 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2024
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Loqtorzi (toripalimab-tpzi) • RX-af01
    2years
    Safety and Efficacy of RX-af01 Combined With PD-1 Antibody (clinicaltrials.gov)
    P1/2, N=14, Recruiting, Sun Yat-sen University
    New P1/2 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    Loqtorzi (toripalimab-tpzi) • RX-af01